About 55% of the US population has been fully vaccinated
Moderna, Inc. CEO of Stefan Bansel said he believed the COVID-19 pandemic could be over in a year as vaccine production continues.
“If you look at the industry-wide expansion of production capacity over the past six months, there should be enough doses available by the middle of next year to vaccinate everyone on this earth. Boosters should also be possible to the extent necessary,” He told the Swiss newspaper Neue Zuercher Zeitung, according to Reuters.
Modena’s Cash Hits $15B, New Vaccine Details Released
Bansel also said that vaccinations would soon be available for infants and he believed normalcy would return “in a year”.
“People who don’t get vaccinated will naturally immunize themselves, because the delta version is so contagious. That’s how we end up in a flu-like situation. You can either get vaccinated and get a good cold. Or you Don’t do that and risk getting sick and possibly ending up in the hospital.”
Bansal’s remarks came after the US Food and Drug Administration (FDA)’s decision to authorize Pfizer-BioNTech booster shots for individuals aged 65 and over and 18 to 64 years of age who are either “severe” are at high risk of COVID-19″ or those who work in high-risk locations.
A single booster is to be given at least six months after people get their first two doses.
Modern, Inc. 50 µg-dose booster under consideration and the U.S. already offered An additional dose of Pfizer-BioNTech or Moderna Vaccines – at least 28 days After getting a second shot – for people with a severely weakened immune system.
According to Bansel, at-risk patients who were last vaccinated “undoubtedly” need a booster and added that he expects governments to approve shots for people who have already been vaccinated.
“Vaccine volume is the biggest limiting factor. With half the dose, we will have three billion doses available worldwide for the coming year, instead of just two billion,” he said.
Modern’s booster shot has the same composition as the original, Reuters reported, with half the dose of the initial dose.
“We are currently testing delta-optimized variants in clinical trials. They will form the basis for booster vaccinations for 2022. We are also trying delta plus beta, the next mutation that scientists believe is That’s a possibility,” Bansel said.
The CEO said that the price of vaccination will not change.
Moderna Vaccine is available under emergency use authorization for individuals 18 years of age and older, and the company has also requested to expand the authorization to adolescents aged 12-17 years.
Get Granthshala Business on the go by clicking here
Granthshala Business’ Kayla Rivas and